HAE (hereditary angiodysplasia)Icatibant Acetate
Icatibant (Firazyr) is a synthetic peptidomimetic drug consisting of ten amino acids, and acts as an effective and specific antagonist of bradykinin B2 receptors. It has been approved in the EU for use in hereditary angioedema, and is under investigation for a number of other conditions in which bradykinin is thought to play a significant role. Icatibant currently has orphan drug status in the United States and FDA approved on August 25, 2011.
Icatibant Acetate is a selective competitive antagonist for the bradykinin B2 receptor. It is indicated for the treatment of acute attacks of hereditary angioedema (HAE). HAE is a rare disorder resulting in periodic attacks of acute edema. It is characterized by a deficiency of functional C1 esterase inhibitor that leads to the overproduction of bradykinin, which triggers vasodilation, vascular permeability, and edema. Icatibant Acetate inhibits bradykinin from binding to the B2 receptor and thereby treats the clinical symptoms of an acute, episodic attack of HAE.
Icatibant Acetate Structural Formula:
Diseases and fields of Icatibant Acetate
|Product||Status||Indication of dosage form||Market|
|Icatibant Acetate||Commercial||HAE (hereditary angiodysplasia)||Overseas|
|Synthesis mode||chemic synthesis，solid phase synthesis|
|Sales markets||Western Europe; Asia; North America; Central/South America|
|Selling Points||International Approvals/Standards|